Concomitant Non-V600E BRAF and KRAS Mutations in Colorectal Carcinoma by Next-Generation Sequencing: A Distinct...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The RAS-RAF-MEK-ERK pathway is frequently altered in colorectal cancer.
• BRAFV600E mutations are actionable drug targets, while KRAS mutations predict response to anti-EGFR therapy.
• Coexistence of non-V600E BRAF and KRAS mutations is uncommon and poorly documented.

Purpose of the Study:

• To report a rare case of colorectal carcinoma with inguinal lymph node metastases.
• To detail the detection of concomitant KRAS and BRAF non-V600E mutations using next-generation sequencing.
• To discuss the clinical, pathological, and therapeutic implications of these coexisting mutations.

Main Methods:

• Next-generation sequencing (NGS) for comprehensive genomic profiling.
• Analysis of clinical and pathological data from a colorectal cancer patient.
• Literature review on coexisting RAS/RAF pathway mutations in colorectal cancer.

Main Results:

• Identification of concurrent KRAS and BRAF non-V600E mutations in a patient with metastatic colorectal carcinoma.
• The patient presented with inguinal lymph node involvement.
• The findings highlight a rare genetic profile within the RAS-RAF-MEK-ERK pathway.

Conclusions:

• Concurrent KRAS and BRAF non-V600E mutations represent a rare but significant molecular subtype in colorectal cancer.
• Accurate molecular profiling is essential for understanding treatment resistance and guiding therapeutic strategies.
• Further research is warranted to elucidate the clinical impact and therapeutic vulnerabilities associated with these combined mutations.